UCSF Adult Antibiogram

These reports are aggregated from clinical isolates submitted to the UCSF clinical microbiology laboratory from patients at the UCSF Parnassus and Mission Bay campuses and are meant to guide clinicians in selecting empiric therapy. Patient characteristics must be incorporated in determining risks and therapy should be modified based on susceptibility testing results when available. Breakpoints for susceptibility are via CLSI guidelines.

See Adult Antibiogram 2019 in classic Table form (PDF)

Methodology Notes

16 Organisms

Citrobacter freundii

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
44 63 98 61 93 84 86 87 95
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

E. coli

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
555 69 99 79 78  (91)* 82 61 94 99
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime ( )* including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Enterobacter cloacae

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
123 66 91 66 94 (98)* 94 91 72 99
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *includes susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Enterococcus faecalis (bloodstream isolates)

Total Isolates AMP NAF CLIN DOX T/S VANC DAP LZD
30 100 N/A N/A 23 N/A 97 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid

Enterococcus faecium (bloodstream isolates)

Total Isolates AMP NAF CLIN DOX T/S VANC DAP LZD
23 13 N/A N/A 30 N/A 39 100* 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. AMP-ampicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin *isolates are susceptible dose-dependent, LZD-linezolid

Klebsiella aerogenes

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
44 77 95 79 100 100 88 81 97
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Klebsiella oxytoca

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
45 84 100 84 91 (98)* 84 84 86 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *(including susceptible dose-dependent isolates), CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Klebsiella pneumoniae

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
206 77 94 80 80 (90)* 83 82 88 97
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Proteus mirabilis

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
122 94 100 95 95 (98)* 88 72 99 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Pseudomonas aeruginosa

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
238 N/A N/a 89 91 97 84 85 89
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Serratia marcescens

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
51 96 100 100 100 100 98 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin

Staphylococcus aureus

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
562 N/A 73 73 91 95 100 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid

Staphylococcus aureus, MRSA

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
148 N/A N/A 56 88 90 100 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid

Staphylococcus aureus, MSSA

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
422 N/A 100 78 93 97 100 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid

Staphylococcus epidermidis

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
248 N/A 38 60 89 51 100 100 100
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid

Streptococcus pneumoniae

Total Isolates PCN CTRX CLIN DOX T/S VANC DAP LZD
562 100 (72)* 100 (83)* 94 94 94 100 N/T N/T
Year: 2019 | Location: Inpatient, all areas
Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin *susceptibility based on meningitis breakpoint, CTRX-ceftriaxone *susceptibility based on meningitis breakpoint, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid, N/T-not tested